Effect of inhibiting ACAT-1 expression on the growth and metastasis of Lewis lung carcinoma

被引：22
作者：
Bi, Minghong [1 ]
Qiao, Xuxu [1 ]
Zhang, Haoran [1 ]
Wu, Huazhang [2 ]
Gao, Zhenyuan [1 ]
Zhou, Hairong [1 ]
Shi, Mohan [1 ]
Wang, Yaping [1 ]
Yang, Jingru [1 ]
Hu, Jianguo [3 ]
Liang, Weichen [4 ]
Liu, Yonghong [4 ]
Qiao, Xujie [4 ]
Zhang, Shanshan [1 ]
Zhao, Zhibiao [1 ]
机构：
[1] Bengbu Med Coll, Affiliated Hosp 1, Dept Oncol, 287 Changhuai Rd, Bengbu 233030, Anhui, Peoples R China
[2] Bengbu Med Coll, Sch Life Sci, Bengbu 233030, Anhui, Peoples R China
[3] Bengbu Med Coll, Anhui Prov Key Lab Tissue Transplantat, Bengbu 233030, Anhui, Peoples R China
[4] Bengbu Med Coll, Grad Dept, Bengbu 233030, Anhui, Peoples R China
来源：
ONCOLOGY LETTERS | 2019年 / 18卷 / 02期
基金：
中国国家自然科学基金;
关键词：
Lewis lung carcinoma; acetyl-CoA acetyltransferase 1; Avasimibe; tumor growth; tumor metastasis; CHOLESTEROL ESTERIFICATION; FACTOR RECEPTOR; ACYL-COENZYME; BREAST-CANCER; T-CELLS; AVASIMIBE; PHOSPHORYLATION; PROLIFERATION; EFFICACY;
D O I：
10.3892/ol.2019.10427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Accumulating evidence suggests that acetyl-CoA acetryltransferase 1 (ACAT-1) may mediate tumor development and metastasis. However, the specific function served by ACAT-1 in lung cancer is not well understood. Therefore, the present study initially verified that ACAT-1 was overexpressed in Lewis lung carcinoma (LLC) tissues compared with non-LLC mice and that this overexpression promoted the proliferation, invasion and metastasis of these LLC samples. Western blotting, immunofluorescence microscopy and flow cytometry allowed the present study to determine that the ACAT-1 inhibitor avasimibe significantly reduced the expression of ACAT-1 in LLC compared with LLC cells that are not treated with avasimibe (P<0.05). A combination of Cell Counting Kit-8 and wound healing assays demonstrated that downregulating ACAT-1 expression sufficiently inhibited the proliferation of LLC cells. Avasimibe promoted LLC cell apoptosis as assessed by a Annexin V/propidium iodide double staining assay. Furthermore, avasimibe inhibited tumor growth in vivo and improved immune responses, with tissue biopsies from LLC model mice exhibiting higher levels of ACAT-1 compared with in healthy controls. Altogether, the results of the present study reveal that avasimibe may inhibit the progression of LLC by downregulating the expression of ACAT-1, which may thus be a potential novel therapeutic target for lung cancer treatment.
引用
收藏
页码：1548 / 1556
页数：9
相关论文
共 50 条
  • [1] Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer
    Allott, Emma H.
    Masko, Elizabeth M.
    Freedland, Alexis R.
    Macias, Everardo
    Pelton, Kristine
    Solomon, Keith R.
    Mostaghel, Elahe A.
    Thomas, George, V
    Pizzo, Salvatore, V
    Freeman, Michael R.
    Freedland, Stephen J.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (02) : 196 - 203
  • [2] Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification
    Antalis, Caryl J.
    Uchida, Aki
    Buhman, Kimberly K.
    Siddiqui, Rafat A.
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2011, 28 (08) : 733 - 741
  • [3] Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
    Bandyopadhyay, Shovik
    Li, Junjie
    Traer, Elie
    Tyner, Jeffrey W.
    Zhou, Amy
    Oh, Stephen T.
    Cheng, Ji-Xin
    [J]. PLOS ONE, 2017, 12 (07):
  • [4] Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
    Behjati, Sam
    Tarpey, Patrick S.
    Haase, Kerstin
    Ye, Hongtao
    Young, Matthew D.
    Alexandrov, Ludmil B.
    Farndon, Sarah J.
    Collord, Grace
    Wedge, David C.
    Martincorena, Inigo
    Cooke, Susanna L.
    Davies, Helen
    Mifsud, William
    Lidgren, Mathias
    Martin, Sancha
    Latimer, Calli
    Maddison, Mark
    Butler, Adam P.
    Teague, Jon W.
    Pillay, Nischalan
    Shlien, Adam
    McDermott, Ultan
    Futreal, P. Andrew
    Baumhoer, Daniel
    Zaikova, Olga
    Bjerkehagen, Bodil
    Myklebost, Ola
    Amary, M. Fernanda
    Tirabosco, Roberto
    Van Loo, Peter
    Stratton, Michael R.
    Flanagan, Adrienne M.
    Campbell, Peter J.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [5] Acyl-coenzyme A Cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines
    Bemlih, Sana
    Poirier, Marie-Denise
    El Andaloussi, Abdeljabar
    [J]. CANCER BIOLOGY & THERAPY, 2010, 9 (12) : 1025 - 1032
  • [6] Cholesterol test for T cells
    Bernard, Nicholas J.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2019, 15 (04) : 189 - 189
  • [7] Mammalian acyl-CoA: cholesterol acyltransferases
    Buhman, KF
    Accad, M
    Farese, RV
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1529 (1-3): : 142 - 154
  • [8] A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer
    Cao, Hai-Ying
    Guo, Xiao-Fang
    Zhu, Xia-Fei
    Li, Sai-Sai
    Zhen, Yong-Su
    [J]. ONCOLOGY REPORTS, 2017, 37 (06) : 3329 - 3340
  • [9] Cellular cholesterol homeostasis and Alzheimer's disease
    Chang, Ta-Yuan
    Yamauchi, Yoshio
    Hasan, Mazahir T.
    Chang, Catherine
    [J]. JOURNAL OF LIPID RESEARCH, 2017, 58 (12) : 2239 - 2254
  • [10] Acyl-coenzyme A: cholesterol acyltransferases
    Chang, Ta-Yuan
    Li, Bo-Liang
    Chang, Catherine C. Y.
    Urano, Yasuomi
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2009, 297 (01): : E1 - E9
12345